DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on November 8, 2006; DOI: 10.1124/dmd.106.009423


0090-9556/07/3502-215-220$20.00
DMD 35:215-220, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.009423v1
35/2/215    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meneses-Lorente, G.
Right arrow Articles by Sohal, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meneses-Lorente, G.
Right arrow Articles by Sohal, B.

Utility of Long-Term Cultured Human Hepatocytes as an in Vitro Model for Cytochrome P450 Induction

Georgina Meneses-Lorente, Christine Pattison, Claire Guyomard, Christophe Chesné, Robert Heavens, Alan P. Watt, and Bindi Sohal

Department of Medicinal Chemistry (Drug Metabolism Section), Merck Sharp and Dohme Research Laboratories, Harlow, Essex, United Kingdom (G.M.-L., C.P., R.H., A.P.W., B.S.); and Biopredic International, Rennes, France (C.G., C.C.)

Cytochrome P450 (P450) induction may have considerable implications for drug therapy. Therefore, understanding the induction potential of a new chemical entity at an early stage in discovery is crucial to reduce the risk of failure in the clinic and help the identification of noninducing chemical structures. Availability of human viable tissue often limits evaluation of induction potential in human hepatocytes. A solution is to increase the time period during which the hepatocytes remain viable. In this study we have investigated the induction of several P450 isozymes in long-term cultured hepatocytes compared with short-term cultured hepatocytes from the same individuals. Short- and long-term cultured primary hepatocytes isolated from each individual were cultured in a 96-well format and treated for 24 h with a range of prototypical P450 inducers and Merck Research Laboratories compounds. CYP3A4, 1A1, 1A2, 2B6, and 2C9 mRNA levels were measured using quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan) from the same cultured hepatocyte wells. CYP3A4, 1A1, 1A2, 2B6, and 2C9 were shown to be inducible in long-term cultured hepatocytes. The -fold induction varied between donors, and between short- and long-term cultured hepatocytes from the same donor. However, this variability can be controlled by normalizing data from each hepatocyte preparation to a positive control. The use of long-term cultured hepatocytes on 96-well plates has proven to be sensitive, robust, and convenient for assessing P450 induction potential of new compound entities during the drug discovery process.


Address correspondence to: Georgina Meneses-Lorente, Merck Sharp & Dohme, Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, UK. E-mail: georgina.meneses-lorente{at}roche.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
L. Svecova, R. Vrzal, L. Burysek, E. Anzenbacherova, L. Cerveny, J. Grim, F. Trejtnar, J. Kunes, M. Pour, F. Staud, et al.
Azole Antimycotics Differentially Affect Rifampicin-Induced Pregnane X Receptor-Mediated CYP3A4 Gene Expression
Drug Metab. Dispos., February 1, 2008; 36(2): 339 - 348.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
V. Dixit, N. Hariparsad, F. Li, P. Desai, K. E. Thummel, and J. D. Unadkat
Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions
Drug Metab. Dispos., October 1, 2007; 35(10): 1853 - 1859.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.